Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths
Youth exposed to antipsychotics may experience several metabolic consequences that often limit the effectiveness of this class of drugs.
The aim of this study was to compare several metabolic markers between subjects who experienced antipsychotic-induced weight gain and untreated obese patients.
Nineteen non-diabetic youth (mean age 159 months, mean body mass index z-score 1.81) experiencing antipsychotic-induced weight gain and an age-, sex-, and body mass index-matched group of non-diabetic obese patients with no record of treatment (n = 19, mean age 147 months, mean body mass index z-score 2) were compared for a wide range of metabolic factors using a Bioplex Multiplex system.
C-peptide, glucose-dependent insulinotropic polypeptide, and adipsin were significantly higher in the antipsychotic-induced weight gain group, whereas visfatin was significantly higher in the untreated obese patients. When age, sex, pubertal status, and body mass index were controlled, C-peptide, glucose-dependent insulinotropic polypeptide, and visfatin remained significant, whereas adipsin fell slightly below the threshold of statistical significance. No other statistically significant difference emerged.
Antipsychotic-induced weight gain and untreated obesity showed some similarities, confirming that levels of some hormones, such as leptin and ghrelin, are related to body mass index rather than to antipsychotic exposure. Some differences were also noted; for example, the antipsychotic-induced weight gain group displayed higher C-peptide, glucose-dependent insulinotropic polypeptide, and adipsin, which may reflect β-cell stress and may suggest susceptibility to insulin resistance and lower visfatin, possibly indicating a lower inflammatory status.
Compliance with Ethical Standards
Conflict of interest
Simone Pisano, Giangennaro Coppola, Gennaro Catone, Marco Carotenuto, Raffaella Iuliano, Vittoria D’Esposito, Serena Cabaro, Emanuele Miraglia del Giudice, Carmela Bravaccio, and Pietro Formisano have no conflicts of interest directly relevant to the content of this study.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board of the University of Campania approved the study.
Consent to participate
All caregivers and patients received a thorough explanation of the purpose of the study and were asked if they were willing to participate; caregivers signed the consent form.
- 2.Pozzi M, Cattaneo D, Baldelli S, Fucile S, Capuano A, Bravaccio C, Sportiello L, Bertella S, Auricchio F, Bernardini R, Ferrajolo C, Guastella G, Mani E, Carnovale C, Pisano S, Rafaniello C, Riccio MP, Rizzo R, Scuderi MG, Sperandeo S, Villa L, Pascotto A, Molteni M, Rossi F, Radice S, Clementi E. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. Eur J Clin Pharmacol. 2016;72:285–93.CrossRefPubMedGoogle Scholar
- 3.Pozzi M, Pisano S, Bertella S, Capuano A, Rizzo R, Antoniazzi S, Auricchio F, Carnovale C, Cattaneo D, Ferrajolo C, Gentili M, Guastella G, Mani E, Rafaniello C, Riccio MP, Scuderi MG, Sperandeo S, Sportiello L, Villa L, Radice S, Clementi E, Rossi F, Pascotto A, Bernardini R, Molteni M, Bravaccio C. Persistence in therapy with risperidone and aripiprazole in pediatric outpatients: a 2-year naturalistic comparison. J Clin Psychiatry. 2016;77:e1601–9.CrossRefPubMedGoogle Scholar
- 4.Rafaniello C, Pozzi M, Pisano S, Ferrajolo C, Bertella S, Sportiello L, Carnovale C, Sullo MG, Cattaneo D, Gentili M, Rizzo R, Pascotto A, Mani E, Villa L, Riccio MP, Sperandeo S, Bernardini R, Bravaccio C, Clementi E, Molteni M, Rossi F, Radice S, Capuano A. Second generation antipsychotics in ‘real-life’ paediatric patients: adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf. 2016;15:1–8.CrossRefPubMedGoogle Scholar
- 6.Pisano S, Catone G, Veltri S, Lanzara V, Pozzi M, Clementi E, Iuliano R, Riccio MP, Radice S, Molteni M, Capuano A, Gritti A, Coppola G, Milone A, Bravaccio C, Masi G. Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists. Ital J Pediatr. 2016;42:51–61.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73:247–59.CrossRefPubMedGoogle Scholar
- 12.Baeza I, Vigo L, de la Serna E, Calvo-Escalona R, Merchán-Naranjo J, Rodríguez-Latorre P, Arango C, Castro-Fornieles J. The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. Eur Child Adolesc Psychiatry. 2017;26:35–46.CrossRefPubMedGoogle Scholar
- 13.Pisano S, Catone G, Coppola G, Carotenuto M, Iuliano R, Tiano C, Montesanto AR, D’Esposito V, Del Giudice EM, Formisano P, Bravaccio C. Different immune signature in youths experiencing antipsychotic-induced weight gain compared to untreated obese patients. J Child Adolesc Psychopharmacol. 2017;27:844–8.CrossRefPubMedGoogle Scholar
- 18.Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, Kelly ME, Chatterjee Bhowmick D, Murano I, Cohen P, Banks AS, Khandekar MJ, Dietrich A, Flier JS, Cinti S, Blüher M, Danial NN, Berggren PO, Spiegelman BM. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158:41–53.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Balõtšev R, Haring L, Koido K, Leping V, Kriisa K, Zilmer M, Vasar V, Piir A, Lang A, Vasar E. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: a 7-month follow-up study. Early Interv Psychiatry. 2017. https://doi.org/10.1111/eip.12457 (Epub ahead of print).PubMedGoogle Scholar
- 27.Bahr SM, Tyler BC, Wooldridge N, Butcher BD, Burns TL, Teesch LM, Oltman CL, Azcarate-Peril MA, Kirby JR, Calarge CA. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl Psychiatry. 2015;5:e652.CrossRefPubMedPubMedCentralGoogle Scholar